会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明公开
    • 당쇄화된 사람 인터페론 알파 동종체
    • GLYCOSYLATED人类干扰素ALPHA ISOFORM
    • KR1020040020830A
    • 2004-03-09
    • KR1020030060941
    • 2003-09-01
    • 씨제이 주식회사
    • 이은정박형기김현석박지숙김연향이현수고형곤오명석
    • C07K14/56
    • C07K14/56
    • PURPOSE: Provided is a glycosylated human interferon alpha isoform, which has improved stability in human body. Therefore, it reduces dose and dosage frequency thereof when clinically applied. CONSTITUTION: A glycosylated human interferon alpha isoform is prepared by forming one or more sequences of Asn-X-Ser/Thr(N-X-S/T) on the amino acid residues: -Cys1-Ser8 (Cys1-Asp-Leu-Pro-Gln-Thr-His-Ser8); -Arg22-Thr52 (Arg22-Arg-Ile-Ser-Leu-Phe-Ser-Cys-Leu-Lys-Asp-Arg-His-Asp-Phe-Gly-Phe-Pro-A sn-Glu-Glu-Phe-Gly-Asn-Gln-Phe-Gln-Lys-Ala-Glu-Thr52); -Ser68; -Asp77; -Lys134-Ser137 (Lys134-Tyr-Ser137); and -Gln158-Glu165 (Gln158-Glu-Ser-Leu- Arg-Ser-Lys-Glu165), and followed by glycosylation, wherein and leucine at amino acid position 26 is substituted by asparagine, histidine and phenylalanine at amino acid position 34 and 36 are substituted by asparagine and serine, respectively, lysine at amino acid position 134 is substituted by asparagine, or all of them are modified. A method for producing the glycosylated human interferon alpha isoform comprises culturing a eukaryotic host cell transformed with an expression vector containing the glycosylated human interferon alpha isoform gene and isolating the glycosylated human interferon alpha isoform from the cultured medium.
    • 目的:提供糖基化的人类干扰素α同工型,其具有改善的人体的稳定性。 因此,临床应用时可降低其剂量和剂量频率。 构成:通过在氨基酸残基:Cys1-Ser8(Cys1-Asp-Leu-Pro-Gln-Leu)上形成一个或多个Asn-X-Ser / Thr(NXS / T)序列而制备糖基化的人类干扰素α同种型 THR-的His-Ser8); -Arg22-Thr52(Arg22-Arg-Ile-Ser-Leu-Phe-Ser-Cys-Leu-Lys-Asp-Arg-His-Asp-Phe-Gly-Phe-Pro-A sn-Glu-Glu-Phe- 甘氨酸-ASN-GLN-PHE-GLN-的Lys-ALA-GLU-Thr52); -Ser68; -Asp77; -Lys134-Ser137(Lys134-Tyr-Ser137); 和Gln158-Glu165(Gln158-Glu-Ser-Leu- Arg-Ser-Lys-Glu165),然后进行糖基化,其中氨基酸位置26处的亮氨酸在氨基酸位置34被天冬酰胺,组氨酸和苯丙氨酸取代, 36分别由天冬酰胺和丝氨酸取代,氨基酸位置134处的赖氨酸被天冬酰胺取代,或者它们全部被修饰。 制备糖基化人干扰素α同种型的方法包括培养用含有糖基化的人干扰素α同种型基因的表达载体转化的真核宿主细胞,并从培养的培养基中分离出糖基化的人干扰素α同种型。
    • 6. 发明公开
    • 당쇄화된 사람 인터페론 알파 동종체
    • GLYCOSYLATED人类干扰素ALPHA ISOFORM
    • KR1020040020817A
    • 2004-03-09
    • KR1020030060431
    • 2003-08-29
    • 씨제이 주식회사
    • 이은정박형기김현석박지숙김연향이현수고형곤오명석
    • C07K14/56
    • C07K14/56
    • PURPOSE: A glycosylated human interferon alpha isoform is provided, which has improved stability in human body and reduces dose and dosage frequency thereof when clinically applied. CONSTITUTION: A glycosylated human interferon alpha isoform is prepared by forming one or more sequences of Asn-X-Ser/Thr(N-X-S/T) on the amino acid residues; -Cys1-Ser8 (Cys1-Asp-Leu-Pro-Gln-Thr-His-Ser8); -Arg22-Thr52 (Arg22-Arg-Ile-Ser-Leu-Phe-Ser-Cys-Leu-Lys-Asp-Arg-His-Asp-Phe-Gly-Phe-Pro-A sn-Glu-Glu-Phe-Gly-Asn-Gln-Phe-Gln-Lys-Ala-Glu-Thr52); -Ser68; -Asp77; -Lys134-Ser137 (Lys134-Tyr-Ser137), and -Gln158-Glu165 (Gln158-Glu-Ser-Leu- Arg-Ser-Lys-Glu165), and followed by glycosylation, wherein leucine at amino acid position 26 is substituted by asparagine, histidine and phenylalanine at amino acid position 34 and 36 are substituted by asparagine and serine, respectively, lysine at amino acid position 134 is substituted by asparagine, or all of them are modified.
    • 目的:提供糖基化人类干扰素α同种型,其在临床应用时具有改善的人体的稳定性并降低其剂量和剂量频率。 构成:通过在氨基酸残基上形成一个或多个Asn-X-Ser / Thr(N-X-S / T)序列来制备糖基化的人类干扰素α同种型; -Cys1-Ser8(Cys1-Asp-Leu-Pro-Gln-Thr-His-Ser8); -Arg22-Thr52(Arg22-Arg-Ile-Ser-Leu-Phe-Ser-Cys-Leu-Lys-Asp-Arg-His-Asp-Phe-Gly-Phe-Pro-A sn-Glu-Glu-Phe- 甘氨酸-ASN-GLN-PHE-GLN-的Lys-ALA-GLU-Thr52); -Ser68; -Asp77; -Lys134-Ser137(Lys134-Tyr-Ser137)和-Gln158-Glu165(Gln158-Glu-Ser-Leu- Arg-Ser-Lys-Glu165),然后糖基化,其中氨基酸26位的亮氨酸被 氨基酸位置34和36处的天冬酰胺,组氨酸和苯丙氨酸分别被天冬酰胺和丝氨酸取代,氨基酸位置134处的赖氨酸被天冬酰胺取代,或者它们都被修饰。